Anthropic reports early progress in accelerating drug development with Claude across six partner organizations

Details

Anthropic’s life sciences team has engaged in deep research partnerships with six organizations (BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group) to apply Claude to various stages of drug development, from target identification to regulatory filings.
In specific case studies, Claude helped Generate Biomedicines create a CAR T-cell design 70% shorter than the standard version, which in lab tests allowed immune cells to produce roughly 10 times as many receptors; for Divergence Labs, Claude generated approximately 35,000 antibody designs in about a month, identifying hits for both binding and dislodging IgE molecules.
Operational efficiencies were demonstrated at Enveda, where Claude reduced human review time for manufacturing documentation by 89% (from over 25 hours to less than three) and caught all 11 issues spotted by human reviewers while flagging seven they missed; at BigHat Biosciences, Claude-guided optimization resulted in leads that bound more than 10x more tightly and clumped more than 100x more slowly.
Anthropic has also acquired Mithril Medicine, a one-person company using Claude to manage operations for rare muscular dystrophy treatments, which achieved promising mouse results in less than 18 months; the company plans to expand these efforts and has launched Claude Science and a Life Sciences Verification Program to support broader adoption.

Key point